

29 January 2025

BEXIMCO PHARMACEUTICALS LIMITED

Board Changes

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or the "Company"; AIM Symbol: BXP, LEI No.: 213800IMBB6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30 November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to this position by IFIC Bank PLC, a shareholder in the Company, and he will serve as a Non-Executive Director.

Mr. Islam has extensive expertise in finance and management at a senior level, having worked at Bangladesh Bank, the central bank of Bangladesh, for 33 years, retiring as an Executive Director in 2014. He currently serves as an independent director of IFIC Bank PLC, a leading full-service private bank based in Dhaka. He is also a Supernumerary Professor at the Bangladesh Institute of Bank Management (BIBM), the national educational institute on banking and finance in Bangladesh.

Mr. A S F Rahman - Chairman of Beximco Pharmaceuticals, commented:

"On behalf of the Board, I would like to thank Ms. Quamrun Naher Ahmed for her contribution to the Board over the past four years, and wish her all the very best for the future.

I am delighted to announce that Mr. Ebtadul Islam is joining Beximco Pharma's Board. He has deep experience from a long career at Bangladesh Bank and we are excited for him to bring this to bear at Beximco Pharma. We are looking forward to working with him as we continue to maintain our focus on growing the business and delivering shareholder value."

Additional disclosure information required by Schedule 2(g) of the AIM Rules for Companies

Mr. Mohammed Ebtadul Islam

In addition to his appointment to the board, Mr. Mohammed Ebtadul Islam, aged 69, holds (or has held) the following directorships/partnerships in the past five years:

Current directorships/partnerships	Previous directorships/partnerships
IFIC Bank PLC	None
IFIC Money Transfer (UK) Limited	
IFIC Investment Limited	

Neither Mr. Islam, nor any person closely associated with him, has any direct or indirect personal interest in the shares of Beximco Pharmaceuticals Limited. As noted above, Mr. Islam has been nominated to the position of Non-Executive Director by IFIC Bank PLC.

There is no further information to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPUQGGUPAGMR